



Guidelines for abstract submission poster presenters

1. GUIDELINES

Abstracts should be prepared strictly according to the following instructions:

Content

- Abstracts should include:
 - brief introduction to the research question
 - aim(s) of the study
 - methods used including statistical analysis methods
 - summary of results containing real data and the outcome of statistical analyses
 - conclusions
- Abstracts must report on high quality original research in the field of neuropsychopharmacology and/or (applied) neuroscience that has not been published whole or in part elsewhere.
- The statements, in particular in the conclusion section, should be balanced.
- No abbreviations or trade names are allowed in the title. However, the generic name may be used.
- Use standard abbreviations for well-established neuropsychopharmaceuticals. Place unusual abbreviations in parentheses after the full word the first time it appears. Clearly identify all neuropsychopharmaceuticals used.
- Please indicate on the online abstract form the topics of your abstract in ranking order.
- A disclosure on potential conflicts of interest (acknowledgement of funding) is requested when submitting an abstract.

Layout

- Abstracts must be submitted in English (UK).
- The title should not exceed 20 words.
- Write the title in lower case letters (except the first letter) and do not put a dot at the end.
- Abstracts should have a minimum of 450 and a maximum of 500 words (excluding references).
- The use of underlined is not permitted. Words that need emphasis should be **bold** or *italics* type.
- Only one table is allowed, please note that graphs and pictures can not be included. Tables cannot be inserted with copy/paste. Please create your table with the help of the 'table button' (top left, middle button).

References (optional)

- Optionally, you can include up to five references to previous publications. In the body text, a publication should be referred to by a consecutive number between brackets, i.e. [1], [2], [3], [4] and [5]. References indicated in the reference list, that are not linked to the body text will be deleted by the publisher.
- Authors are responsible for the accuracy of references. Only published articles and those in press (the journal should be stated) may be included; unpublished results and personal communications should be cited as such in the body text.
- It is the author's responsibility that the references are provided in accordance with *ENP journal referencing guidelines*, see the following examples:

Reference to a journal publication

[1] Chamberlain, S.R., Hampshire, A., Muller, U., Rubia, K., Del Campo, N., 2009. Atomoxetine modulates right inferior frontal activation during inhibitory control. A pharmacological functional magnetic resonance imaging study. *Biol. Psychiatry* 65(4), 550-555.

Reference to the DSM-5

[1] American Psychiatric Association, 2013. Diagnostic and statistical manual of mental disorders, fifth ed. American Psychiatric Association Publishing, Washington.



Reference to a book

[1] Strunk Jr., W., White, E.B., 1979. The Elements of Style, third ed. Macmillan, New York.

Reference to a chapter in a book

[1] Williams, K., 1980. Pharmacological dilemmas in psychiatry, in: Weaver, R., Smith, L.K., Perspective on psychiatry, second ed. Theme Press, Cornwall, 301-315.

Reference to a website

[1] McArthur, J., 2014. The link between schizophrenia and dementia, a new perspective. Available from: www.biopsychiatry.com/schizophrenia-dementia. [Accessed: 12 May 2015].

Reference to a DOI

[1] De Jong, A., 2015. Developments in the field of neuropsychopharmacology. Pharm. Journal, this issue, <http://dx.doi.org/10.2215.j.pharmjournal.2014.09.003>.

For more example please have a look at the model abstracts file.

Authors

- Insert the author's initials, last name and institute details as indicated on the on-line form. Do not add any titles or degrees: Prof, Dr, etc.
- The person submitting the abstract should be the author presenting the poster (presenting author). All communication will be done with the presenting author.

2. EVALUATION AND PUBLICATION

Review

An abstract is eligible for review when:

- The abstract is submitted according to the guidelines on or before the deadline.
- The presenting author has registered and paid the congress registration fee within 2 weeks after submitting the abstract, and no later than 15 April 2019.

The abstracts submitted will be reviewed for:

- Presentation at the congress by means of a poster and/or e-poster.
- Publication in the congress supplement to the journal *European Neuropsychopharmacology**

* An abstract that is not accepted for publication in the journal supplement can still be presented at the congress by means of an e-posters. The titles and authors of these abstracts will be listed in the congress programme booklet, in the ECNP app and in the online programme.

All submitted abstracts (from registered presenting authors) will be evaluated by a scientific review committee. Authors will be informed of the committee's decision by e-mail before 1 July 2019. ECNP will not enter into discussion about the outcome. Please also note that no changes to the abstract text are possible after review has taken place.

Abstracts will be available via our online scientific programme on <https://2019.ecnp.eu> and on the ECNP app.



32ND ECNP CONGRESS

7-10 SEPTEMBER 2019

COPENHAGEN

The future of
CNS treatments



Conditions for publication

Abstracts accepted for publication will be published **after the congress** in a congress supplement to the journal *European Neuropsychopharmacology*, but **only if**:

- The presenting author attends the congress
and
- The poster is displayed in the poster area on the day of the poster presentation
and
- The presenting author presents the poster on the day and time on which the presentation has been scheduled (please note that we will check on site to make sure people stick to their presenting schedule)

Please note: If the presenting author does not meet all three criteria mentioned above the abstract will not be published in the congress supplement to the journal *European Neuropsychopharmacology*.

The publisher of *European Neuropsychopharmacology* holds all publication rights including copyright.